611 GATEWAY BOULEVARD, SUITE 900, SOUTH SAN FRANCISCO, CA
Material disclosure
Reports First Quarter 2026 Financial Results
Termination of License Agreement with Eli Lilly - Rigel Pharmaceuticals
Financial Results, Press Release
Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers
Provides Business Update and 2026 Outlook
Presents Updated Data from the Ongoing Phase 1b Study Evaluating R289 in Patients with Lower-Risk MDS at the 67th ASH Annual Meeting and Exposition
Reports Third Quarter 2025 Financial Results and Provides Business Update
Q1
FY 2025
Q3
Q2
FY 2024
Registration Statement for Securities to be Offered to Employees
Effectiveness Notice
Registration Statement for Securities Offered under a Shelf Registration
Additional Proxy Materials
Definitive Proxy Statement
PRE 14A
Statement of Changes in Beneficial Ownership
Schedule 13G - Ownership Report